Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bad Precedent? Plan B Rx/OTC Labeling May Have Implications For Existing OTCs ­– NEJM

This article was originally published in The Pink Sheet Daily

Executive Summary

Nonprescription drugs, such as aspirin and ibuprofen, could be reevaluated if Barr chooses simultaneous Rx/OTC marketing of levonorgestrel at the same dose for both populations.

You may also be interested in...

Plan B OTC Submission Deemed "Not Approvable"

Barr will have to detail a mechanism for drugstores to screen women less than 16 years of age for nonprescription use of the emergency contraceptive. FDA's decision goes against the recommendation of its advisory panels.

Medicare Coverage Policy Change Opens Up Commercial Market Pathway – If Biden Likes It

Modification to ‘reasonable and necessary’ definition in MCIT final rule offers new avenue for drug manufacturers to get products covered in Part B. The Biden Administration will have to decide whether it will keep the Trump regulation unchanged.

Flaws Of ‘Virtual’ Advisory Committees Highlighted At Aducanumab Panel

The intensely negative advisory committee for Biogen’s proposed Alzheimer’s therapy was a shocker. Would it have happened if US FDA had been able to convene an in-person event instead of a ‘virtual’ one?





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts